Search Results - "HIRAKATA, Hideki"

Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis by Tsuruya, Kazuhiko, Hirakata, Hideki

Get full text

Postdialysis blood pressure is a better predictor of mortality than predialysis blood pressure in Japanese hemodialysis patients: the Japan Dialysis Outcomes and Practice Patterns Study by Tsuruya, Kazuhiko, Kanda, Eiichiro, Nomura, Takanobu, Iseki, Kunitoshi, Hirakata, Hideki

“…Blood pressure (BP) is reportedly a predictor of mortality in hemodialysis (HD) patients; however, it is unclear whether pre- or postdialysis BP has greater…”
Get full text

Validation Study of Oxford Classification of IgA Nephropathy: The Significance of Extracapillary Proliferation by Katafuchi, Ritsuko, Ninomiya, Toshiharu, Nagata, Masaharu, Mitsuiki, Koji, Hirakata, Hideki

“…BACKGROUND AND OBJECTIVES The Oxford classification of IgA nephropathy (IgAN) includes mesangial hypercellularity, endocapillary hypercellularity, segmental…”
Get full text

Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width by Ito, Kyoko, Yokoyama, Keitaro, Nakayama, Masaaki, Fukagawa, Masafumi, Hirakata, Hideki

“…The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders…”
Get full text

Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder by Fukagawa, Masafumi, Yokoyama, Keitaro, Koiwa, Fumihiko, Taniguchi, Masatomo, Shoji, Tetsuo, Kazama, Junichiro James, Komaba, Hirotaka, Ando, Ryoichi, Kakuta, Takatoshi, Fujii, Hideki, Nakayama, Msasaaki, Shibagaki, Yugo, Fukumoto, Seiji, Fujii, Naohiko, Hattori, Motoshi, Ashida, Akira, Iseki, Kunitoshi, Shigematsu, Takashi, Tsukamoto, Yusuke, Tsubakihara, Yoshiharu, Tomo, Tadashi, Hirakata, Hideki, Akizawa, Tadao

Get full text

Modified Creatinine Index and the Risk of Bone Fracture in Patients Undergoing Hemodialysis: The Q-Cohort Study by Yamada, Shunsuke, MD, PhD, Taniguchi, Masatomo, MD, PhD, Tokumoto, Masanori, MD, PhD, Yoshitomi, Ryota, MD, Yoshida, Hisako, PhD, Tatsumoto, Narihito, MD, Hirakata, Hideki, MD, PhD, Fujimi, Satoru, MD, PhD, Kitazono, Takanari, MD, PhD, Tsuruya, Kazuhiko, MD, PhD

“…Background Hemodialysis patients are at increased risk for bone fracture and sarcopenia. There is close interplay between skeletal muscle and bone. However, it…”
Get full text

Cardiothoracic Ratio and All-Cause Mortality and Cardiovascular Disease Events in Hemodialysis Patients: The Q-Cohort Study by Yotsueda, Ryusuke, MD, Taniguchi, Masatomo, MD, PhD, Tanaka, Shigeru, MD, PhD, Eriguchi, Masahiro, MD, PhD, Fujisaki, Kiichiro, MD, PhD, Torisu, Kumiko, MD, PhD, Masutani, Kosuke, MD, PhD, Hirakata, Hideki, MD, PhD, Kitazono, Takanari, MD, PhD, Tsuruya, Kazuhiko, MD, PhD

“…Background Cardiothoracic ratio by chest radiography is commonly used to assess volume status. Little is known about the relationships between cardiothoracic…”
Get full text

Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial by Ogata, Hiroaki, Fukagawa, Masafumi, Hirakata, Hideki, Kagimura, Tatsuo, Akizawa, Tadao

“…Background Coronary artery calcification (CAC) is predictive of cardiovascular events. We assessed whether a non-calcium-based phosphate binder, lanthanum…”
Get full text

Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD by Yokoyama, Keitaro, Hirakata, Hideki, Akiba, Takashi, Fukagawa, Masafumi, Nakayama, Masaaki, Sawada, Kenichi, Kumagai, Yuji, Block, Geoffrey A

“…Ferric citrate hydrate is a novel iron-based phosphate binder being developed for hyperphosphatemia in patients with CKD. A phase 3, multicenter, randomized,…”
Get full text

The combination of malnutrition-inflammation and functional status limitations is associated with mortality in hemodialysis patients by Kanda, Eiichiro, Lopes, Marcelo Barreto, Tsuruya, Kazuhiko, Hirakata, Hideki, Iseki, Kunitoshi, Karaboyas, Angelo, Bieber, Brian, Jacobson, Stefan H., Dasgupta, Indranil, Robinson, Bruce M.

“…The identification of malnutrition-inflammation-complex (MIC) and functional status (FS) is key to improving patient experience on hemodialysis (HD). We…”
Get full text

Development and Validation of a Prediction Rule Using the Oxford Classification in IgA Nephropathy by Tanaka, Shigeru, Ninomiya, Toshiharu, Katafuchi, Ritsuko, Masutani, Kosuke, Tsuchimoto, Akihiro, Noguchi, Hideko, Hirakata, Hideki, Tsuruya, Kazuhiko, Kitazono, Takanari

“…The risk assessment for developing ESRD remains limited in patients with IgA nephropathy (IgAN). The aim of this study was to develop and validate a prediction…”
Get full text

Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies by Akizawa, Tadao, Nangaku, Masaomi, Yamaguchi, Takuhiro, Koretomo, Ryosuke, Maeda, Kazuo, Yamada, Osamu, Hirakata, Hideki

“…Enarodustat (JTZ‐951) is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed for treating anemia in chronic kidney disease. Two open‐label,…”
Get full text

Association of dialysis-related amyloidosis with lower quality of life in patients undergoing hemodialysis for more than 10 years: The Kyushu Dialysis-Related Amyloidosis Study by Tsuruya, Kazuhiko, Arima, Hisatomi, Iseki, Kunitoshi, Hirakata, Hideki

“…Dialysis-related amyloidosis (DRA) commonly develops in patients undergoing long-term dialysis and can lead to a decline in activities of daily living and…”
Get full text

Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial by Akizawa, Tadao, Nangaku, Masaomi, Yamaguchi, Takuhiro, Arai, Masanobu, Koretomo, Ryosuke, Maeda, Kazuo, Miyazawa, Yuya, Hirakata, Hideki

“…Enarodustat (JTZ-951) is an orally available hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin levels in the…”
Get more information

Association of blood pressure after peritoneal dialysis initiation with the decline rate of residual kidney function in newly-initiated peritoneal dialysis patients by Kuroki, Yusuke, Hori, Kei, Tsuruya, Kazuhiko, Matsuo, Dai, Mitsuiki, Koji, Hirakata, Hideki, Nakano, Toshiaki, Kitazono, Takanari

“…Background Lower blood pressure (BP) levels are linked to a slower decline of kidney function in patients with chronic kidney disease (CKD) without kidney…”
Get full text

A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study by Akizawa, Tadao, Nangaku, Masaomi, Yamaguchi, Takuhiro, Koretomo, Ryosuke, Maeda, Kazuo, Miyazawa, Yuya, Hirakata, Hideki

“…Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease…”
Get full text

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease by Yamamoto, Hiroyasu, Nishi, Shinichi, Tomo, Tadashi, Masakane, Ikuto, Saito, Kazuhide, Nangaku, Masaomi, Hattori, Motoshi, Suzuki, Takahiro, Morita, Satoshi, Ashida, Akira, Ito, Yasuhiko, Kuragano, Takahiro, Komatsu, Yasuhiro, Sakai, Ken, Tsubakihara, Yoshiharu, Tsuruya, Kazuhiko, Hayashi, Terumasa, Hirakata, Hideki, Honda, Hirokazu

“…Renal anemia is a complication of chronic kidney disease. Guidelines for safe and effective treatment in patients with renal anemia are needed. The Japanese…”
Get full text

2011 update Japanese Society for Dialysis Therapy Guidelines of Vascular Access Construction and Repair for Chronic Hemodialysis by Kukita, Kazutaka, Ohira, Seiji, Amano, Izumi, Naito, Hidemune, Azuma, Nakanobu, Ikeda, Kiyoshi, Kanno, Yutaka, Satou, Takashi, Sakai, Shinji, Sugimoto, Tokuichiro, Takemoto, Yoshiaki, Haruguchi, Hiroaki, Minakuchi, Jun, Miyata, Akira, Murotani, Noriyoshi, Hirakata, Hideki, Tomo, Tadashi, Akizawa, Tadao

Get full text

Clinical Significance of Fronto-Temporal Gray Matter Atrophy in Executive Dysfunction in Patients with Chronic Kidney Disease: The VCOHP Study by Tsuruya, Kazuhiko, Yoshida, Hisako, Haruyama, Naoki, Fujisaki, Kiichiro, Hirakata, Hideki, Kitazono, Takanari

“…It is well known that cognitive impairment in patients with chronic kidney disease (CKD) is characterized by executive dysfunction, rather than memory…”
Get full text

2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease by Tsubakihara, Yoshiharu, Nishi, Shinichi, Akiba, Takashi, Hirakata, Hideki, Iseki, Kunitoshi, Kubota, Minoru, Kuriyama, Satoru, Komatsu, Yasuhiro, Suzuki, Masashi, Nakai, Shigeru, Hattori, Motoshi, Babazono, Tetsuya, Hiramatsu, Makoto, Yamamoto, Hiroyasu, Bessho, Masami, Akizawa, Tadao

“…The Japanese Society for Dialysis Therapy (JSDT) guideline committee, chaired by Dr Y. Tsubakihara, presents the Japanese guidelines entitled “Guidelines for…”
Get full text